Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical value of FAT1 mutations to indicate the immune response in colorectal cancer patients.

Genomics - 1 Mar 2024

Zhu Wei, Yang Lan, Gao Yu, Zhou Yi, Shi Yuqian, Liu Kaihua, Yu Ruoying, Shao Yang, Zhang Wentong, Wu Guosheng, He Junjun

Abstract excerpt

Immunotherapy is currently approved for CRC whose tumors have high MSI-H. To find additional biomarkers for immunotherapy in CRC, targeted sequencing was performed on tumor tissues from a discovery cohort of 161 CRC patients. Validation cohorts from the cBioPortal were also used for survival and tumor cell infiltration analyses. The FAT1-mutated CRC group often co-occurred with MSI events and displayed a higher...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cadherins
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunity

Share to Microsatellite Instability

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to Prognosis

Source

Identifiers

PMID: 38364976
DOI: 10.1016/j.ygeno.2024.110808

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical value of FAT1 mutations to indicate the immune response in colorectal cancer patients.PMID 38364976Read ↗

Comprehensive analysis reveals the molecular heterogeneity and the differences in prognosis and immunotherapy sensitivity in hypermutated colorectal cancer.Semantic proximity Read ↗

MTUS1 is Correlated with Immune Infiltration and Acts as a Promising Diagnostic and Prognostic Biomarker for Colorectal Cancer.Semantic proximity Read ↗

Apolipoprotein C1 as a Novel Biomarker for Evaluating Immunotherapy Drug Responses and Clinical Prognosis for Microsatellite Unstable Colorectal CancerSemantic proximity Read ↗

Multi-omics analysis of the potential of MACC1 as a biomarker and therapeutic target for colonic adenocarcinomaSemantic proximity Read ↗

Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.Semantic proximity Read ↗

Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.Semantic proximity Read ↗

MUC4 mutation correlates with tumor mutation burden and the immune microenvironment in colorectal cancerSemantic proximity Read ↗

Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapySemantic proximity Read ↗

Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients.Semantic proximity Read ↗

Multi‐omic characterization of consensus molecular subtype 1 ( CMS1 ) colorectal cancer with dampened immune response improves precision medicineSemantic proximity Read ↗

Prognostic Biomarker MUC4 Mutations in Colon Adenocarcinoma Correlating with Tumor MicroenvironmentSemantic proximity Read ↗

CSMD1 mutation is associated with prognosis, tumor mutation burden, and immunophenotype in non-metastatic colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.